Works matching DE "THERAPEUTIC use of antineoplastic agents"

Results: 5000

THE PROTECTIVE ROLE OF INTESTINAL MICROBIOTA IN COLORECTAL CANCER TREATMENT: A SCOPING REVIEW.

Published in:

Texto & Contexto Enfermagem, 2024, v. 33, p. 1, doi. 10.1590/1980-265X-TCE-2024-0109en

By:

Rosa Thiesen Cunha, Jéssica;
Faiz, Elissandra Maria;
de Souza Bueno, Elizete Maria;
Rosa da Fonseca, Eliana;
Ortiz Hammes, Thais;
Serdotte Freitas Cardoso, Adriana;
Becker Vieira, Leticia;
Echer, Isabel Cristina

Publication type:

Article

QUIMIO EM CASA: APPLICATION FOR FAMILY MEMBERS OF CHILDREN AND ADOLESCENTS USING ORAL ANTINEOPLASTIC AGENTS.

Published in:

Texto & Contexto Enfermagem, 2022, v. 31, p. 1, doi. 10.1590/1980-265X-TCE-2021-0414en

By:

Alvernaz Silva Franco, Gabriele;
da Silva, Liliane Faria;
Seixas, Flavio Luiz;
Garcia Bezerra Góes, Fernanda;
Teixeira de Araújo Pacheco, Sandra;
de Montenegro Medeiros de Moraes, Juliana Rezen

Publication type:

Article

Neoadjuvant pembro shows benefit in MIBC.

Published in:

Urology Times, 2021, v. 49, n. 10, p. 7

By:

BRODERICK, JASON M.

Publication type:

Article

Olaparib/pembrolizumab, focal therapy, and ultrasonic propulsion of stones: AUA 2021 highlights.

Published in:

2021

By:

HART, JANELLE;
HARRIS, JASON;
LOVELY, BRITTANY;
BRODERICK, JASON M.;
SAYLOR, BENJAMIN P.

Publication type:

Proceeding

UroPipeline.

Published in:

Urology Times, 2021, v. 49, n. 10, p. 5

By:

BRODERICK, JASON M.

Publication type:

Article

Emerging Treatment Options for the Management of Metastatic Castration-Resistant Prostate Cancer.

Published in:

Urology Times, 2021, v. 49, n. 9, p. 33

By:

GOMELLA, LEONARD

Publication type:

Article

What have been the biggest changes in the way you treat prostate cancer?

Published in:: 2021
Publication type:: Interview

EV-301 investigator discusses enfortumab vedotin: "Significant survival advantage" vs chemotherapy was observed.

Published in:

2021

By:

TUCKER, NICHOLE

Publication type:

Interview

Analysis backs genomic testing for optimal apalutamide use in nmCRPC: Microarray-based assay identified potential biomarkers of response to treatment.

Published in:

Urology Times, 2021, v. 49, n. 8, p. 16

By:

BRODERICK, JASON M.

Publication type:

Article

Pembrolizumab/axitinib RCC survival bene?t is sustained in long-term results: Median OS was 45.7 months with the combination vs 40.1 months with sunitinib.

Published in:

Urology Times, 2021, v. 49, n. 7, p. 17

By:

BRODERICK, JASON M.

Publication type:

Article

NCCN adds lenvatinib/pembrolizumab to Category 1 recommendation.

Published in:

Urology Times, 2021, v. 49, n. 5, p. 34

By:

Kahl, Kristie L.

Publication type:

Article

CTC mutations may predict hormone therapy outcomes in mCRPC.

Published in:

Urology Times, 2021, v. 49, n. 5, p. 22

By:

Sternberg, Audrey

Publication type:

Article

Rucaparib plus enzalutamide shows early promise in metastatic CRPC.

Published in:

Urology Times, 2021, v. 49, n. 5, p. 22

By:

Broderick, Jason M.

Publication type:

Article

PHASE 3 TRIAL TO EXPLORE RCC COMBINATION.

Published in:

Urology Times, 2021, v. 49, n. 4, p. 34

By:

Broderick, Jason M.

Publication type:

Article

Combination of belzutifan plus cabozantinib is active in advanced RCC: Treatment shrank tumors in 88% of patients and led to a disease control rate of 90%.

Published in:

Urology Times, 2021, v. 49, n. 4, p. 34

By:

Harris, Jason

Publication type:

Article

Bipolar androgen therapy sensitizes CRPC to subsequent treatment: Patient-reported QOL data consistently favored BAT over enzalutamide, investigators report.

Published in:

Urology Times, 2021, v. 49, n. 4, p. 11

By:

Broderick, Jason M.

Publication type:

Article

UroPipeline.

Published in:

Urology Times, 2021, v. 49, n. 4, p. 7

By:

BRODERICK, JASON M.

Publication type:

Article

Noncastrate advanced prostate cancer guideline receives update: Panel outlines 4 standards of care for the initial treatment of noncastrate metastatic disease.

Published in:

Urology Times, 2021, v. 49, n. 3, p. 11

By:

Broderick, Jason M.

Publication type:

Article

Onvansertib is active in patients with abiraterone-resistant prostate cancer: More than one-third of patients undergoing treatment had disease control at 12 weeks.

Published in:

Urology Times, 2021, v. 49, n. 3, p. 10

By:

Broderick, Jason M.

Publication type:

Article

Apalutamide plus abiraterone reduces risk of progression in metastatic CRPC: Radiographic progression-free survival benefit was sustained across prespecified subgroups.

Published in:

Urology Times, 2021, v. 49, n. 3, p. 9

By:

Broderick, Jason M.

Publication type:

Article

Olaparib antitumor activity sustained across HRR gene subtypes in metastatic CRPC: Greatest benefit occurred in patients with BRCA1/BRCA2 mutations, data indicate.

Published in:

Urology Times, 2021, v. 49, n. 3, p. 8

By:

Broderick, Jason M.

Publication type:

Article

Enzalutamide plus ADT improves PFS in men with bone and/or lymph node metastases.

Published in:

Urology Times, 2021, v. 49, n. 2, p. 11

By:

Hilton, Lisette

Publication type:

Article

FDA approves label update for darolutamide in nonmetastatic CRPC.

Published in:

Urology Times, 2021, v. 49, n. 2, p. 7

By:

BRODERICK, JASON M.

Publication type:

Article

PARP inhibitors: What urologists need to know.

Published in:

2021

By:

ANTONARAKIS, EMMANUEL S.

Publication type:

Interview

Subgroup data sustain enzalutamide PFS benefit in nonmetastatic CRPC.

Published in:

Urology Times, 2021, v. 49, n. 1, p. 18

By:

Ternyila, Danielle

Publication type:

Article

How to get started with immunotherapy.

Published in:

Urology Times, 2021, v. 49, n. 1, p. 1

By:

Hilton, Lisette

Publication type:

Article

Expert provides update on treatments for BCG-unresponsive NMIBC: Pembrolizumab and nadofaragene firadenovec show promise in non--muscle-invasive bladder cancer.

Published in:

Urology Times, 2020, v. 48, n. 12, p. 28

By:

Broderick, Jason M.

Publication type:

Article

Expert: 2020 marks dawn of the precision medicine era in prostate cancer: FDA approval of PARP inhibitors olaparib and rucaparib has launched new era, investigator says.

Published in:

Urology Times, 2020, v. 48, n. 12, p. 19

By:

Broderick, Jason M.

Publication type:

Article

UroPipeline.

Published in:

Urology Times, 2020, v. 48, n. 12, p. 8

By:

BRODERICK, JASON M.

Publication type:

Article

Why is rucaparib response higher in BRCA2-mutated prostate cancer? Investigators present 2 hypotheses for variance in sensitivity to PARP inhibition.

Published in:

Urology Times, 2020, v. 48, n. 11, p. 23

By:

Broderick, Jason M.

Publication type:

Article

Cabozantinib combo induces clinical activity in advanced ccRCC.

Published in:

Urology Times, 2020, v. 48, n. 10, p. 41

By:

Kahl, Kristie L.

Publication type:

Article

Nephrectomy after immunotherapy can achieve CR in selected patients.

Published in:

Urology Times, 2020, v. 48, n. 10, p. 40

By:

Kuznar, Wayne

Publication type:

Article

FDA approval is sought for nivolumab/ cabozantinib combo in kidney cancer.

Published in:

Urology Times, 2020, v. 48, n. 10, p. 6

By:

BRODERICK, JASON M.

Publication type:

Article

Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use.

Published in:

2024

By:

Nie, Tina

Publication type:

Correction Notice

Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 1, p. 1, doi. 10.1007/s40267-024-01045-0

By:

Nie, Tina

Publication type:

Article

Preferably pre-empt pathological scars, or pick from a plethora of therapies.

Published in:

Drugs & Therapy Perspectives, 2024, v. 40, n. 1, p. 22, doi. 10.1007/s40267-023-01040-x

By:

Fenton, Caroline;
Lamb, Yvette N.

Publication type:

Article

The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 12, p. 432, doi. 10.1007/s40267-023-01038-5

By:

Munzone, Elisabetta;
Fabi, Alessandra;
Buono, Giuseppe;
Caputo, Roberta;
Montagna, Emilia;
Negri, Mara;
Nuzzo, Francesco;
Palazzo, Antonella;
Paris, Ida;
Conti, Luca;
Baggi, Anna;
Franzini, Jean Marie;
De Laurentiis, Michelino

Publication type:

Article

The role of belzutifan, an inhibitor of hypoxia-inducible factor, for renal cell carcinoma in adults with Von Hippel–Lindau disease: a review.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 11, p. 388, doi. 10.1007/s40267-023-01031-y

By:

Schwartz, Anne M.;
Fakhre, Waddih;
Jin, Kevin;
Bollich, Victoria E.;
Ahmadzadeh, Shahab;
Shekoohi, Sahar;
Kaye, Alan D.

Publication type:

Article

Tisotumab vedotin-tftv in previously treated recurrent or metastatic cervical cancer: a profile of its use in the USA.

Published in:

Drugs & Therapy Perspectives, 2022, v. 38, n. 9, p. 382, doi. 10.1007/s40267-022-00939-1

By:

Kim, Esther S.;
Al-Salama, Zaina T.

Publication type:

Article

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA.

Published in:

Drugs & Therapy Perspectives, 2022, v. 38, n. 6, p. 261, doi. 10.1007/s40267-022-00922-w

By:

Markham, Anthony;
Al-Salama, Zaina T.

Publication type:

Article

Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?

Published in:

Drugs & Therapy Perspectives, 2022, v. 38, n. 5, p. 222, doi. 10.1007/s40267-022-00915-9

By:

Morgado, Sandra;
Silva, Mafalda;
Fonseca, Olímpia;
Roque, Fátima;
Morgado, Manuel

Publication type:

Article

Initiation of Oral Endocrine Therapy and Survival Benefit Among Women with Early-Stage Breast Cancer.

Published in:

Journal of Women's Health (15409996), 2024, v. 33, n. 11, p. 1509, doi. 10.1089/jwh.2023.0971

By:

Qian, Jingjing;
Truong, Bang

Publication type:

Article

Primary immunosuppressive TNI-based conditioning regimens in pediatric patients treated with haploidentical hematopoietic cell transplantation.

Published in:

Strahlentherapie und Onkologie, 2022, v. 198, n. 1, p. 66, doi. 10.1007/s00066-021-01840-y

By:

Wegener, D.;
Lang, P.;
Paulsen, F.;
Weidner, N.;
Zips, D.;
Ebinger, M.;
Holzer, U.;
Döring, M.;
Heinzelmann, F.

Publication type:

Article

Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity.

Published in:

2020

By:

Paireder, Matthias;
Jomrich, Gerd;
Kristo, Ivan;
Asari, Reza;
Rieder, Erwin;
Beer, Andrea;
Ilhan-Mutlu, Aysegül;
Preusser, Matthias;
Schmid, Rainer;
Schoppmann, Sebastian F.

Publication type:

journal article

Risikostratifizierung der Lungentoxizität einer Kombination von Bestrahlung der gesamten Lunge und Hochdosischemotherapie bei Patienten mit Ewing-Sarkom und Lungenmetastasen – eine Übersicht.

Published in:

2020

By:

Scobioala, Sergiu;
Eich, Hans Theodor

Publication type:

journal article

Diffusion-weighted imaging as a follow-up modality for evaluation of major salivary gland function in nasopharyngeal carcinoma patients: a preliminary study.

Published in:

2020

By:

Fan, Wen-jun;
Teng, Feng;
Luo, Yan-rong;
Yu, Wei;
Zhang, Qian;
Lu, Yi-ping;
Ma, Lin

Publication type:

journal article

Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.

Published in:

2020

By:

Zhou, Ying;
Yan, Tiansheng;
Zhou, Xiaojuan;
Cao, Peng;
Luo, Chunli;
Zhou, Lin;
Xu, Yong;
Liu, Yongmei;
Xue, Jianxin;
Wang, Jin;
Wang, Yongsheng;
Lu, You;
Liang, Binmiao;
Gong, Youling

Publication type:

journal article

Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts.

Published in:

2020

By:

Baehr, A.;
Trog, D.;
Oertel, M.;
Welsch, S.;
Kröger, K.;
Grauer, O.;
Haverkamp, U.;
Eich, H. T.

Publication type:

journal article

Einfluss der präoperativen Therapie auf die prognostische Gensignatur CINSARC: Translationale Forschungsergebnisse einer Phase-1-Studie der deutschen interdisziplinären Sarkomstudiengruppe (GISG 03).

Published in:

2020

By:

Jakob, Jens;
Lesluyes, Tom;
Simeonova-Chergou, Anna;
Wenz, Frederik;
Hohenberger, Peter;
Chibon, Frederic;
Le Guellec, Sophie

Publication type:

journal article

Ergebnisse der lokoregionalen Strahlentherapie bei metastatischen kastrationsresistenten und mit Abirateronacetat behandelten Prostakarzinompatienten.

Published in:

2019

By:

Yildirim, Berna Akkus;
Onal, Cem;
Kose, Fatih;
Oymak, Ezgi;
Sedef, Ali Murat;
Besen, Ali Ayberk;
Aksoy, Sercan;
Guler, Ozan Cem;
Sumbul, Ahmet Taner;
Muallaoglu, Sadık;
Mertsoylu, Huseyin;
Ozyigit, Gokhan

Publication type:

journal article